Wells Fargo analyst Larry Biegelsen says that Boston Scientific has informed him that total mesh sales are about $100M and that the products impacted by the FDA recall represent a subset of those sales or about $25M or 0.3% of total sales. The firm had previously stated that the mesh sales impacted by the FDA recall were about $100M in 2018. Biegelsen notes that the lower figure should be "more manageable" for the company. According to the analyst, Boston Scientific is surprised and disappointed by the FDA's decision, which impacts Uphold LITE Vaginal Support System and the Xenform Soft Tissue Repair Matrix for pelvic organ prolapse.

Evercore ISI analyst Vijay Kumar raised the firm's price target on Boston Scientific to $78 from $72 and keeps an Outperform rating on the shares as the firm said the company reported "solid results and there wasn't much to pick on." While EP franchise acceleration driven by Farapulse PFA launch "is generally well known" by the Street, the firm says it doesn't think "anyone expected ~86% US growth and ~72% International growth."

Baird analyst David Rescott raised the firm's price target on Boston Scientific to $84 from $79 and keeps an Outperform rating on the shares. The firm noted its 1Q24 revenue/adjusted EPS beat was the biggest over the past several years and one of the most compelling in diversified LGCP MedTech.

Stifel raised the firm's price target on Boston Scientific to $83 from $70 and keeps a Buy rating on the shares. The firm said the company delivered "solid" Q1 outperformance, underpinned by "important" new product launches. Looking ahead to 2024 and beyond, Stifel believes Boston Scientific could continue outperforming their Loan Repayment Program and the firm's projections.

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here